home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Events -> Courses and Workshops  

Three Key Aspects of Risk Management during Phase 3 Clinical Trials

  March 17, 2008  
Drug Information Association, Online
Apr 23 2008

Risk Minimization Action Plans (Risk MAPs) evolve as clinical and safety data emerge in a product’s lifecycle. Risk MAPs should begin to be developed as early in the product life cycle as possible, prior to an NDA filing. The phase 3 time period offers an opportunity to inform a post-marketing risk minimization program. This webinar will teach you how to:·Incorporate a Risk MAP within a pre-marketing clinical trial;·Evaluate clinical trial data as a basis for developing a RiskMAP strategy; and·Use the phase 3 program to test and refine Risk MAP tools.
Organized by: Drug Information Association
Invited Speakers: Annette Stemhagen, Dr PH, FISPE.Vice President, Epidemiology and Risk ManagementUnited Biosource CorporationUnited States.
Deadline for Abstracts: -
Registration: http://www.diahome.org/DIAHOME/Education/FindEducationalOffering.aspx?productID=16994&eventType=Webinar
E-mail: dia@diahome.org
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.